Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The phenomenon of cancer recurrence remains one of the most significant challenges in modern oncology, particularly in the context of…
Read MoreYOU MAY HAVE MISSED
